WW International, Inc. (WW), the company formerly known as Weight Watchers, has spent the past two years in an unusually difficult position: rebuilding its balance sheet through Chapter 11 while simultaneously reinventing itself around GLP-1 weight-loss medications. With the stock trading near $13 after a volatile year, the question of whether it can climb back toward a $28 analyst price target requires separating a credible turnaround from a still-levered, shrinking core business.
Analyst coverage of WW has thinned considerably since its 2025 bankruptcy, and the targets that remain are unusually dispersed. Based on current ratings, the average analyst price target is approximately $28.33 — rounded to $28 for this analysis — with a low near $20 and a high near $35, according to MarketWatch data reflecting three ratings. The consensus recommendation sits around Hold/Overweight, indicating a neutral-to-cautiously-positive view rather than conviction.
The dispersion reflects genuine disagreement about the pace of the company's pivot. More cautious analysts emphasize the persistent decline in the legacy behavioral-subscription business, where revenue fell roughly 23% year over year in a recent quarter. More constructive views focus on the clinical segment, where revenue rose to about 25% of the total and is expected to keep climbing. Earlier post-emergence targets were notably higher — for example, Morgan Stanley held a $41 target and Lucid Capital Markets published a $60 target in mid-2025 — but those figures now look stale given the stock's subsequent decline. This underscores how quickly sentiment around the stock has reset.
WW last traded near $12.75, with a market capitalization of roughly $127 million. Reaching $28 would require an approximate 120% gain, which is a very large move by any standard. The stock has already fallen more than 50% year to date and trades well below its 52-week high of $38.38 set in November 2025 and its post-emergence peak near $46.95.
The path to $28 would almost certainly require investors to re-rate the company as a durable clinical-weight-management platform rather than a declining diet brand. That means sustained growth in clinical (Med+) subscriptions, stabilization of the behavioral base, and meaningful progress on deleveraging. For fiscal 2026, management guided to revenue of $620 million to $635 million and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $105 million to $115 million — a framework that assumes the shift toward medication-supported care continues while the traditional subscription business keeps contracting.
The clearest support for a higher stock price forecast is the company's transition into the GLP-1 market. WW now offers clinicians who can prescribe medications, including GLP-1s and hormone replacement therapy, layered on top of its behavioral programs. Clinical revenue has grown to roughly a quarter of the business, up from about 16% in 2025, and management expects that share to keep rising. The company also reported better-than-expected fourth-quarter results, with revenue of about $162.8 million beating estimates and a narrower-than-expected loss.
Operationally, adjusted gross margins have held near the low-70s percentage range even as the mix shifts toward more labor-intensive clinical services, supported by automation and efficiency gains. A dramatically improved balance sheet is another factor: total term-loan debt was reduced to roughly $423 million from $1.6 billion before restructuring, and the company has been repurchasing some debt at a discount.
The principal obstacle is that the legacy behavioral business is still shrinking. Behavioral subscription revenue declined more than 20% year over year, and management itself anticipates that overall clinical subscriber counts may ease modestly in the near term as marketing spend normalizes. If the clinical segment does not grow quickly enough to offset those declines, revenue and earnings expectations could be revised lower.
The balance sheet remains a real constraint. The company's term loan carries an interest rate around 10.5% (SOFR plus 6.8%), and its debt of more than $400 million is several times its $127 million equity market value. High interest expense limits cash available for reinvestment, and any slowdown in cash generation could pressure the stock. Macroeconomic factors — including consumer spending pressures — and intense competition in the weight-loss and telehealth space add further uncertainty.
From a technical standpoint, the stock's 52-week low near $8.37 represents a key support level, with the $10 round-number area providing a psychological cushion above it. On the upside, the $28 target sits in a gap between the current price and the November 2025 high of $38.38, which now functions as major overhead resistance. The wide distance between the recent low and prior highs reflects the stock's exceptional volatility since emerging from bankruptcy, making the $28 objective a long way from today's market structure rather than a modest extension.
Analyst price targets generally reflect a roughly 12-month research horizon, though the actual horizon varies by firm. Investors tracking the $28 objective should watch upcoming earnings and guidance updates, particularly the mix between clinical and behavioral revenue, subscriber trends, adjusted EBITDA progress, and any additional debt-reduction activity. Changes in analyst ratings or target prices — which have been volatile for this name — and developments in the broader GLP-1 and telehealth markets are also worth monitoring.
For traders seeking a systematic view of shifting sentiment, Tickeron's AI Daily Buy/Sell Signals offer an additional layer of analysis. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening allows. Exploring the signals can help investors stay ahead of the shifts in momentum that often accompany volatile names like WW.
The $28 target represents a substantial re-rating of WW International — roughly 120% above its recent price — and is grounded in a small number of widely dispersed analyst estimates rather than a firm consensus. The supporting case is real: a fast-growing clinical segment, a healthier post-bankruptcy balance sheet, and improving margins. But the obstacles are equally real: a still-contracting behavioral business, high-cost debt that dwarfs the equity value, and thin coverage that leaves the stock exposed to sharp revisions. Whether WW reaches $28 depends on the clinical pivot outpacing the legacy decline — a path that remains plausible but far from assured. No outcome should be treated as guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, WW has been loosely correlated with AIRS. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if WW jumps, then AIRS could also see price increases.